VANCOUVER, British Columbia, Jul 20, 2007 -- ProtoKinetix Inc.'s (OTCBB: PKTX) Board of Directors is pleased to announce the appointment of Max Arella, PhD, to their Board. Dr. Arella brings with him a wealth of experience in academic research, scientific consultation and the start up of technological companies. He is trilingual, a motivated professional and a technological entrepreneur who achieves concrete results. Currently Dr. Arella is involved with scientific development from the laboratory to the marketplace.
Dr. Arella received a PhD in Virology from the Institut Armand Frappier / Universite de Rouen (France) in 1983. He did his Post-doctorate in Biotechnology at the Roche Institute of Molecular Biology, New Jersey (USA) in 1984.
Since 1984, as a consultant and entrepreneur he has advised numerous clients and businesses as well as assisted in the management of companies with technological positioning and negotiations. He has also evaluated markets for several companies with a view to determine the most effective ways to commercialize technological discoveries coming from universities, research institutes and hospitals.
About ProtoKinetix:
ProtoKinetix Inc. is a Biotechnical Company that has developed and patented a family of synthetic antifreeze glycoproteins (AAGP(TM)) for human and veterinary medicine, the pharmaceutical and cosmetic industries. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is currently negotiating commercial and collaborative agreements on several of the proven and tested applications. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors Company Office: Suite #1500 885 West Georgia Street Vancouver, BC V6C 3E8
ProtoKinetix Inc.
Blair Henderson,
604-687-9887
denotes parts of the page that are editable
